SCHEMBL122648

SCHEMBL122648

CC(C)(C)OC(=O)N1CCN(c2nccnc2N2CCCCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.53
GPR119 Q8TDV5 5/20 0.50
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
POLB P06746 1/20 0.48
KIT P10721 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
GRIA1 P42261 1/20 0.46
GBA1 P04062 1/20 0.46
ACHE P22303 1/20 0.46
MAP4K4 O95819 1/20 0.46
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
OGFRL1 Q5TC84 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28501446 0.86 SMN1; SMN2 (0.59) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL2385593 0.86 GPR119 (0.50) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL23560764 0.86 GPR119 (0.50) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL8923132 0.85 POLB (0.55) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL5236520 0.85 POLB (0.55) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL30592010 0.84 POLB (0.60) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL7061217 0.84 GPR119 (0.49) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL124268 0.84 POLB (0.60) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL26107084 0.83 KIT (0.48) PDE10AGPR119CKS1BSKP1SKP2
SCHEMBL31651955 0.83 GPR119 (0.49) PDE10AGPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2201002-B1 5-HT7 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2012-03-07 EP disclosed
US-7910588-B2 5-HT7 receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-22 US disclosed
US-20100197700-A1 5-HT7 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197700-A1 5-HT7 RECEPTOR ANTAGONISTS HTR7, HTR1A, HTR2C PDE10A 703/4885GPR119 233/4885CKS1B 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.